Modular Medical, Inc. SEC 10-K Report

Modular Medical, Inc., a pre-revenue medical device company focused on designing, developing, and commercializing innovative insulin pumps, has released its Form 10-K report for the fiscal year ended March 31, 2025. The report provides a comprehensive overview of the company's financial performance, business operations, strategic initiatives, and the challenges it faces as it moves towards commercializing its products.

Financial Highlights

• Net Loss: $18.8 million, compared to a net loss of $17.5 million for the previous year.
• Net Loss Per Share: $0.51, a decrease from $0.78 in the previous year, reflecting an increase in the number of shares outstanding.
• Total Operating Expenses: $19.0 million, up from $17.5 million, primarily due to higher research and development costs.
• Research and Development: $14.7 million, a 14.1% increase driven by higher personnel costs and increased depreciation and amortization expenses.
• General and Administrative: $4.4 million, a 6.4% decrease mainly due to reductions in stock-based compensation and marketing expenses.

Business Highlights

• Business Overview: Modular Medical is focused on designing, developing, and commercializing innovative insulin pumps. Their initial product, the MODD1, aims to simplify insulin pump usage and expand the market to a broader audience, including both Type 1 and Type 2 diabetes patients.
• FDA Clearance and Product Launch: In September 2024, the company received FDA clearance to market and sell the MODD1 insulin pump in the United States. Initial shipments are planned for the quarter ending September 30, 2025, with a second 510(k) premarket notification for an updated version called the Pivot, expected to launch by March 31, 2026.
• Product Differentiation: The MODD1 and its successor, the Pivot, are designed to address shortcomings of existing insulin pumps, such as complexity, bulkiness, and cost. The company's products focus on ease of use, affordability, and a modern design to appeal to a wider market segment.
• Manufacturing and Production: The company has partnered with Phillips Medisize, a tier-one medical device manufacturer, to manage and operate production, enabling rapid scaling of production to higher volumes at lower costs.
• Future Product Development: The company plans to transition from the MODD1 to the Pivot, a tubeless version of the product, and aims to obtain CE mark clearance for both products to enter European markets by the first quarter of 2026.
• Market Opportunity: The company identifies a significant market opportunity among 'Almost Pumpers,' individuals who are aware of insulin pumps but have not adopted them due to cost, complexity, and other barriers. They estimate a $3 billion total addressable market.
• Technological Advancements: The MODD1 pump utilizes modern, miniaturized technologies, making it smaller and lighter than competitors while holding more insulin. The company is also exploring multi-chamber pump solutions for future applications beyond diabetes.
• Regulatory and Compliance: The company is navigating comprehensive federal, state, and local regulations, including FDA requirements for medical devices, and is preparing for European regulatory compliance to expand their market reach.
• Strategic Partnerships and Distribution: The company plans to use a differentiated go-to-market strategy, employing distributors and a small direct sales force to target primary care physicians and diabetes educators, aiming to increase pump adoption among new users.

Strategic Initiatives

• Commercialization Focus: Modular Medical is focused on the commercialization of its MODD1 insulin pump, having received FDA clearance in September 2024. The company aims to commence initial shipments by the quarter ending September 30, 2025, and is working towards obtaining regulatory clearance for its Pivot Product in 2026.
• Capital Management: The company has primarily financed its operations through private placements and public offerings of common stock and warrants. In March 2025, Modular Medical completed a private placement of 6,247,656 units, raising approximately $12 million. Concurrently, a direct private placement with a foreign investor raised an additional $0.5 million. The company also completed a public offering in November 2024, raising net proceeds of $7.3 million. As of March 31, 2025, the company had a cash balance of $13.1 million.
• Future Outlook: Modular Medical plans to increase R&D expenses in fiscal 2026 to support the hiring of additional personnel and the development of its Pivot Product. The company anticipates an increase in general and administrative expenses as it builds a sales and marketing organization and implements systems to support product commercialization. The company is actively seeking additional capital through equity or debt securities to support its operations and future growth initiatives.

Challenges and Risks

• Going Concern: The company may not be able to continue as a going concern due to insufficient cash reserves and the need for additional funding.
• Pre-Revenue Status: As a pre-revenue company with a history of operating losses, there is uncertainty about achieving profitability.
• Funding Requirements: Substantial additional funding is needed for product development and operations, which may not be available or could dilute existing stockholders.
• Regulatory Risks: The company must obtain regulatory approvals in the U.S. and other jurisdictions, which can be costly and time-consuming.
• Technological Obsolescence: Advances in diabetes treatment could render the company's products obsolete.
• Dependence on Key Personnel: The company's success is heavily reliant on key personnel and the ability to attract and retain skilled employees.
• Third-Party Reliance: The company depends on third parties for manufacturing and regulatory submissions, which could impact product development timelines.
• Market Competition: Competitors may develop more effective, safer, or cheaper products, impacting the company's market position.
• Intellectual Property Risks: The company must protect its intellectual property and may face litigation over patent rights.
• Insurance and Reimbursement: The lack of insurance coverage and reimbursement for its products could hinder market adoption.
• Market Risks: The company is exposed to market risks, including potential fluctuations in the cost of raw materials and components due to supply chain disruptions. Additionally, changes in international trade policies and tariffs could impact the cost structure and pricing of the company's products. The company is also vulnerable to foreign currency exchange rate fluctuations, which may affect its financial results.

SEC Filing: Modular Medical, Inc. [ MODD ] - 10-K - Jun. 20, 2025